

Please type a plus sign (+) inside this box ? ☐

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (use as many sheets as necessary)		Application Number	To Be Assigned
		Filing Date	February 12, 2004
		First Named Inventor	Yu et al.
		Group Art Unit	To Be Assigned
		Examiner Name	To Be Assigned
Sheet 1 of 2	Attorney Docket Number	PF160D3	

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CF	AA	09/912,292		ROSEN, et al.	NOT PUBLISHED	pp. 1-75 (pp. 1 & 2 partially redacted); portion of Table 2; and SEQ ID NOS:7343, 7345, 7350, 7352, 7370, 18786, 20998, 23047, and 43554
	AB	5,714,350		CO, et al.	02-98	
	AC	5,766,856		IMANI, et al.	06-98	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
CH	AD		WO92/14837		THE GENERAL HOSPITAL CORP.	09-03-92		
	AE		WO95/27057		CHUGAI SEIYAKU KABUSHIKI KAISHA	10-12-95		
	AF		WO96/06861		NOVO NORDISK A/S	03-07-96		
	AG		WO97/03190		SAGAMI CHEMICAL RESEARCH CENTER	01-30-97	(See reference AE)	

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
CD	AH	CHIU et al., "An Adherens Junction Protein Is a Member of the Family of Lactose-binding Lectins," <i>J. Biol. Chem.</i> , 269(50):31770-31776 (1994)			
	AI	GenBank Accession No. Q02817, GUM et al., "Mucin 2 Precursor (Intestinal Mucin 2) (10-01-00)			
	AJ	Geneseq Accession No. W11841, KAMATA et al., "Human Galectin-4-like protein," (01-20-97)			
	AK	GUM et al., "Molecular Cloning of Human Intestinal Mucin (<i>MUC2</i>) cDNA," <i>J. Biol. Chem.</i> , 269(4):2440-2446 (01-28-94)			
	AL	GUM et al., "The Human <i>MUC2</i> Intestinal Mucin Has Cysteine-rich Subdomains Located Both Upstream and Downstream in its Central Repetitive Region," <i>J. Biol. Chem.</i> , 267(30):21375-21383 (10-25-92)			
	AM	HAUSER et al., "hP1.B, a human P-domain peptide homologous with rat intestinal trefoil factor, is expressed also in the ulcer-associated cell lineage and the uterus," <i>PNAS</i> (USA) 90:6961-6965 (8-1-93)			
	AN	LOWE et al., "Structure and methylation patterns of the gene encoding human carbonic anhydrase I," <i>J. Biol. Chem.</i> , 267:21375-21383 (9-14-90)			

Examiner	Catherine Joyce	Date Considered	12/1/06
----------	-----------------	-----------------	---------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Please type a plus sign (+) inside this box ?



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (use as many sheets as necessary)				Complete If Known	
				Application Number	To Be Assigned
				Filing Date	February 12, 2004
				First Named Inventor	Yu et al.
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
				Attorney Docket Number	PF160D3
Sheet	2	PF160 D2	2		

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document Office ³ Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
<div style="font-size: 2em;">CQ</div> <div style="font-size: 4em; margin-top: 20px;">↓</div>	AO	MORENO et al., "Detection of Hematogenous Micrometastasis in Patients with Prostate Cancer," <i>Advances in Brief</i> , TJU, 1025 Walnut Street, Suite 1112, Philadelphia, PA, pp. 6110-6112 (11-1-92)		
	AP	ODA et al., "Soluble Lactose-binding Lectin from Rat Intestine with Two Different Carbohydrate-binding Domains in the Same Peptide Chain," <i>J. Biol. Chem.</i> , 268:5929-5939 (03-10-93)		
	AQ	PAPADOPOULOS, et al., "Mutation of a <i>mutL</i> Homolog in Hereditary Colon Cancer," <i>Science</i> , 263:1625-1629 (03-18-94)		
	AR	RECHRECHE, et al., "Cloning and Expression of the mRNA of Human Galectin-4, an S-type Lectin Down-regulated in Colorectal Cancer," <i>Eur. J. Biochem.</i> , 248:225-230 (August 15, 1997)		
	AS	Swiss-prof32 database, Accession No. Q0786, GUM et al., (06-01-1994)		
	AT	TARDY et al., "Purification and characterization of the N-terminal domain of galectin-4 from rat small intestine," <i>FEBS Lett.</i> , 359(2-3):169-172 (1995)		
	AU	TORIBARA et al., "MUC-2 Human Small Intestinal Mucin Gene Structure," <i>J. Clin. Invest.</i> , 88(3):1005-1013 (09-91)		
	AV	XU, et al., "cDNA for the Carboxyl-terminal Region of a Rat Intestinal Mucin-like Peptide," <i>J. Biol. Chem.</i> , 267(8):5401-5407 (March 15, 1992)		

Examiner <i>Catherine Joyce</i>	Date Considered <i>12/1/04</i>
---------------------------------	--------------------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.